Drug Product

Guiding difficult to develop drug molecules from preclinical to clinical by resolving solubility, bioavailability, physical form and stability challenges

Aragen supports clinical candidates across preclinical and clinical development stages through its integrated discovery and development capabilities. Our scientific expertise spans formulation development, solid-state chemistry, material science, and analytics. We specialize in resolving complex challenges—including solubility, bioavailability, physical form, and stability—to enable successful drug product advancement.

Our formulation and analytical laboratories supported by multidisciplinary teams, ensure development of robust dosage forms while minimizing drug substance requirements. A dedicated technology transfer team ensures seamless scale-up and clinical manufacturing to support clinical trials and regulatory submissions.

Aragen’s GMP-compliant formulations facility for NCE molecules has a capacity of one million doses per annum as of 31 March 2026.

Why Aragen?

Strong Scientific Expertise

• Formulation and Analytical Development Support from Discovery through CMC Development
• Deep expertise in pre-formulation, material science, and solid-state chemistry
• Integrated formulation and analytical characterization capabilities

Proven Technology Platforms

• Spray Dried Dispersions (SDDs/ASDs)
• Nanosuspensions
• Peptides and complex molecules
• Experience supporting biotech and pharma sponsors across formulation and analytical development programmes.

Dosage Forms Developed

• Oral Solids: DiB, DiC, Immediate Release (IR), Controlled Release (CR), SDDs
• Topicals and other non-oral dosage forms

Dedicated Infrastructure

• Suites for preclinical, solid-state/material science, and pre-formulation
• Clinical formulation, method development, validation & stability labs
• cGMP clinical drug product manufacturing facility (solid orals for Phase I–II)

Proven Track Record

• Pre-formulation and formulation development support to over 200 NCEssince Fiscal 2022
• Supported clinical development for over 40 drug productsduring Fiscals 2026, 2025 and 2024.
• We have delivered GMP clinical manufacturing and QP release for over 50 clinical batches within two years of operations during Fiscals 2026 and 2025.
• Team of experienced scientists and subject matter experts (including PhDs)